IMUNON Reports Interim ProgressionFree Survival and Overall Survival Data in Phase 12 OVATION 2 Study in Advanced Ovarian Cancer

LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and next-generation vaccines, announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study. IMNN-001 is the Company’s IL-12 gene-mediated immunotherapy…Read More